Congratulations to our CEO, President and Founder, Dr. Emil Kakkis, on being honored as BIO’s 2019 Henri A. Termeer Biotechnology Visionary Award recipient for his transformative work in rare diseases. Read more.
September 10,
2019
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)
September 4,
2019
Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
September 3,
2019
GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102